<DOC>
	<DOCNO>NCT02322398</DOCNO>
	<brief_summary>The purpose retrospective study assess outcome In Vitro Fertilization ( IVF ) accord type medication use control ovarian stimulation ( COS ) . The study compare pregnancy rate obtain 398 patient receive COS recombinant Follicle Stimulating Hormone ( rFSH ) plus recombinant Luteinising Hormone ( rLH ) 2:1 ratio vs. one observe 450 patient treated human Menopausal Gonadotropin ( hMG ) , stratify result accord number retrieve oocyte .</brief_summary>
	<brief_title>Ovarian Stimulation With Recombinant Gonadotropins vs. Human Menopausal Gonadotropin In Vitro Fertilization</brief_title>
	<detailed_description>Data retrospectively collect clinical chart In Vitro Fertilization ( IVF ) Unit database . Among 3,416 case record database , patient classify expected poor responder and/or expect normal responder , require average daily gonadotropin dose 150-300 IU , select . A total 848 patient matched criterion include final analysis ; , 398 ( Group A ) stimulate rFSH+rLH , whereas 450 ( Group B ) treat hMG . Patients Group A ( n=398 ) stimulate either start dose 150-300 International Units per day ( IU/d ) recombinant Follicle Stimulating Hormone ( rFSH ) plus 75-150 IU/d recombinant Luteinising Hormone ( rLH ) 2:1 ratio . On day 6-7 ovarian stimulation , gonadotropin dose adapt accord ovarian response , always maintain rFSH : rLH ratio . Patients Group B ( n=450 ) receive 150-300 IU/d human Menopausal Gonadotropin , eventually adjust dose day 6-7 ovarian stimulation . Either medication administer within `` long '' protocol Gonadotropin-releasing Hormone ( GnRH ) -agonist `` short '' protocol GnRH-antagonist . The COS regimen ( type protocol type medication ) prescribe absence pre-fixed criterion time prescription different physician Unit , base choice appropriate dosage clinical experience , consider parameter age , small antrall follicle count basal day 3 FSH . The classical `` long '' protocol perform administer GnRH-agonist buserelin ( 900 mcg/d intranasally ) day 21 precede cycle . In `` short '' protocol , GnRH-antagonist cetrorelix start subcutaneous dose 0.25 mg/d accord flexible schedule , least one follicle â‰¥14 mm diameter observe ultrasound ( US ) . COS monitor transvaginal US plus serum estradiol ( E2 ) measurement perform every second day stimulation day 6-7 . From stimulation day 6-7 onward , checkpoint perform least one dominant follicle reach 18 mm diameter , appropriate E2 level . At point , ovulation trigger inject subcutaneously 10,000 IU human Chorionic Gonadotropin , transvaginal US-guided oocyte aspiration ( OPU ) perform approximately 36-37 hour hCG injection local anesthesia ( paracervical block ) . Classical IVF ICSI follow , accord clinical indication . After two day vitro culture , embryos score 1-3 transferred uteri use soft catheter US guidance . The luteal phase support administer 180 mg/d natural progesterone 15 day . Pregnancy assess serum hCG assay 15 day embryo transfer confirm least one gestational sac visualize transvaginal US two week .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>infertility need undergo IVF circulate basal FSH 6.5 UI/l circulate AMH 0.12 ng/ml basal antral follicle count 3 15 circulate basal FSH 6.5 UI/l circulate AMH 0.1 ng/ml 2 ng/ml basal antral follicle count 3 15</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>